Crossmark

Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2025-012377

Published Online: 2026-02-11

Published Print: 2026-02

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Villano, John L https://orcid.org/0000-0001-5583-0093
Luke, Jason J https://orcid.org/0000-0002-1182-4908
Julian, Ricklie

Fountzilas, Christos https://orcid.org/0000-0003-3837-5644
Patel, Manish R https://orcid.org/0000-0003-2752-945X
Chisamore, Michael J

Bhattacharya, Pranob

Takeshita, Shigeru

Soukharev, Serguei

Yamada, Shunsuke

Zhang, Leshi

Wentzel, Kristopher P
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct06171178 at ClinicalTrials.gov

Documents that mention this clinical trial

Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors
https://doi.org/10.1136/jitc-2025-012377

520 Safety and tolerability of ASP1012, an oncolytic virus, in adults with locally advanced or metastatic solid tumors: Results from a first-in-human, phase 1, open-label, dose-escalation study
https://doi.org/10.1136/jitc-2025-sitc2025.0520
Funding

Funding for this research was provided by:

Astellas Pharma Inc. (N/A)
License Information

License valid from 2026-02-11